Significance: Hypertension is the leading risk factor causing mortality and morbidity
worldwide. Angiotensin (Ang) II, the most active metabolite of the renin–angiotensin system …

Established cardiac fibrosis (ECF) with symptomatic heart failure preserved ejection fraction
represents an ever-increasing segment of the hypertensive population. The regression of …

Oral administration of the peptide alamandine has antihypertensive and anti-fibrotic effects
in rats. This work aimed to determine whether subcutaneous alamandine injection would …

Haemodynamic disorders are common clinical findings in hypertension and lead to adverse
cardiovascular events. However, the haemodynamic conditions in hypertension models are …

Alamandine is the newest identified peptide of the renin-angiotensin system (RAS) and has
protective effects in the cardiovascular system. Although the involvement of classical RAS …

We have recently described a new peptide of the renin-angiotensin system, alamandine, a
derivative of angiotensin-(1–7). Mas-related G protein-coupled receptor member D (MrgD) …

Background: Transforming growth factor type beta 1 (TGF-β1) produces skeletal muscle
atrophy. Angiotensin-(1-7)(Ang-(1-7)), through the Mas receptor, prevents the skeletal …

Clinical studies have shown a correlation between thyroid disorders and cardiac diseases.
High levels of triiodothyronine (T3) induce cardiac hypertrophy, a risk factor for cardiac …

The role of the intrarenal renin‐angiotensin system (RAS) in the pathophysiology of
malignant hypertension is not fully understood. Accumulating evidence indicates that the …

The angiotensin-(1–7)[ANG-(1–7)]/Mas receptor pathway is currently recognized as a
counterbalancing mechanism of the renin-angiotensin system in different pathophysiological …